ACT-One proves its flexibility
This article was originally published in Clinica
Early data on Advanced Coronary Technology's ACT-One stent show that it is comparable to devices already on the market but with the advantage that it is radiopaque. A group from Toho University Hospital in Tokyo, Japan, implanted 23 ACT-One stents during a pilot study. They were successful in 90% of lesions but had to resort to using Palmaz-Schatz stents in six cases. Five stents slipped off the balloon during the study. Only three were successfully recovered.